17 Capital Partners LLC Sells 636 Shares of Danaher Corporation $DHR

17 Capital Partners LLC trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 10.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,492 shares of the conglomerate’s stock after selling 636 shares during the period. 17 Capital Partners LLC’s holdings in Danaher were worth $1,085,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. MGO One Seven LLC lifted its holdings in Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock valued at $5,145,000 after purchasing an additional 20,813 shares during the last quarter. Chicago Capital LLC increased its stake in shares of Danaher by 11.6% during the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after purchasing an additional 1,391 shares during the period. UniSuper Management Pty Ltd lifted its holdings in Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock worth $34,954,000 after purchasing an additional 2,667 shares during the last quarter. Nvwm LLC lifted its holdings in Danaher by 20.4% during the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after purchasing an additional 1,204 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. boosted its stake in Danaher by 1.9% in the 2nd quarter. ASR Vermogensbeheer N.V. now owns 322,924 shares of the conglomerate’s stock valued at $63,787,000 after purchasing an additional 6,136 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Down 1.3%

Shares of DHR opened at $222.58 on Thursday. The firm has a 50 day simple moving average of $207.29 and a two-hundred day simple moving average of $201.61. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The company has a market cap of $157.22 billion, a P/E ratio of 45.89, a P/E/G ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter last year, the company posted $1.71 EPS. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were issued a $0.32 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Insider Activity

In related news, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Teri List sold 3,298 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the transaction, the director owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This represents a 13.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 33,026 shares of company stock worth $7,195,987. Corporate insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research report on Tuesday, September 2nd. Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. TD Cowen lifted their price objective on shares of Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $243.39.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.